Mitral stenosis follow up: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{Mitral stenosis}} {{CMG}}; {{AE}} {{Rim}} ==Overview== Regular follow up is recommended among patients with asymptomatic mitral stenosis (MS) and preserved left..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Regular follow up is recommended among patients with asymptomatic mitral stenosis (MS) and preserved [[left ventricular ejection fraction]].<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= 129 | issue= 23 | pages= 2440-92 | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref> | Regular follow up is recommended among [[Patient|patients]] with [[asymptomatic]] mitral stenosis (MS) and preserved [[left ventricular ejection fraction]].<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= 129 | issue= 23 | pages= 2440-92 | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref> | ||
==Follow Up== | ==Follow Up== | ||
Echocardiography is performed for follow up among asymptomatic patients with MS to assess the left ventricular ejection fraction (LVEF) and end-systolic dimension. The frequency of follow up with an [[echocardiogram]] among asymptomatic patients with MS and normal LVEF is as follows:<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= 129 | issue= 23 | pages= 2440-92 | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref> | [[Echocardiography]] is performed for follow up among [[asymptomatic]] [[Patient|patients]] with MS to assess the left ventricular ejection fraction (LVEF) and end-systolic dimension. The frequency of follow up with an [[echocardiogram]] among [[asymptomatic]] [[Patient|patients]] with MS and normal LVEF is as follows:<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= 129 | issue= 23 | pages= 2440-92 | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref> | ||
* Progressive MS, stage B (mitral valve area >1.5 cm<sup>2</sup>): every 3-5 years | * Progressive MS, stage B ([[mitral valve]] area >1.5 cm<sup>2</sup>): every 3-5 years | ||
* Severe MS, stage C (mitral valve area 1.0-1.5 cm<sup>2</sup>): every 1-2 years | * Severe MS, stage C ([[mitral valve]] area 1.0-1.5 cm<sup>2</sup>): every 1-2 years | ||
* Severe MS, stage C (mitral valve area <1.0 cm<sup>2</sup>): every year | * Severe MS, stage C ([[mitral valve]] area <1.0 cm<sup>2</sup>): every year | ||
==References== | ==References== | ||
Latest revision as of 14:41, 10 April 2020
|
Mitral Stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mitral stenosis follow up On the Web |
|
American Roentgen Ray Society Images of Mitral stenosis follow up |
|
Risk calculators and risk factors for Mitral stenosis follow up |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
Regular follow up is recommended among patients with asymptomatic mitral stenosis (MS) and preserved left ventricular ejection fraction.[1]
Follow Up
Echocardiography is performed for follow up among asymptomatic patients with MS to assess the left ventricular ejection fraction (LVEF) and end-systolic dimension. The frequency of follow up with an echocardiogram among asymptomatic patients with MS and normal LVEF is as follows:[1]
- Progressive MS, stage B (mitral valve area >1.5 cm2): every 3-5 years
- Severe MS, stage C (mitral valve area 1.0-1.5 cm2): every 1-2 years
- Severe MS, stage C (mitral valve area <1.0 cm2): every year
References
- ↑ 1.0 1.1 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (23): 2440–92. doi:10.1161/CIR.0000000000000029. PMID 24589852.